Searchable abstracts of presentations at key conferences in endocrinology

ea0012p41 | Diabetes, metabolism and cardiovascular | SFE2006

Type II diabetes mellitus presenting with diabetic ketoacidosis in a young obese Caucasian male

Hameed S , Lumbers T , Winocour PH

A 19 year old Caucasian male presented with nausea and malaise. In the past medical history he had been obese since childhood with hyperphagia and abnormal food seeking behaviour. His father was obese and had type I diabetes mellitus. His mother was also obese and had impaired glucose tolerance.On examination he was morbidly obese (body mass index 46.9 Kg/M2) and had axillary acanthosis nigracans. He had clinical features of hypovolaemic shock...

ea0010p20 | Clinical case reports/Governance | SFE2005

New onset diabetes associated with the atypical antipsychotic olanzapine

Mehta S , Hameed A , Patel D , Christen A , Mather H , Valabhji J

Schizophrenia is associated with higher risk of Type 2 diabetes. There are several reports of Type 2 diabetes presenting as diabetic ketoacidosis, particularly in young obese African-Caribbean subjects. We report 3 cases of new onset diabetes presenting with diabetic ketoacidosis (see Table 1) in African-Caribbean males treated with olanzapine for chronic schizophrenia.Table 1 Metabolic parameters on admissionCase</td...

ea0010p21 | Clinical case reports/Governance | SFE2005

Non-alcoholic steatohepatitis (NASH) in a patient with Type 1 diabetes

Mehta S , Hameed A , Theofanoyiannis P , Robinson S , Valabhji J , Elkeles R

Non-alcoholic steatohepatitis is part of the spectrum of non-alcoholic fatty liver disease. It is characterised by triglyceride deposition in the liver associated with a lobular hepatitis and elevated circulating aminotransferases. It is associated with insulin resistance and commonly occurs in Type 2 diabetes but is much less widely recognised in patients with Type 1 diabetes.A 29 year old Caucasian male with longstanding Type 1 diabetes presented with ...

ea0019oc20 | Cardiovascular metabolism | SFEBES2009

The novel peptide prokineticin-2 potently inhibits food intake in rodents and is a potential novel anti-obesity therapy

Bataveljic A , Gardiner J , Patel N , Bewick G , Roy D , Cooke J , Campbell D , Semjonous N , Murphy K , Hameed S , Prosser H , Jethwa P , Ebling F , Vickers S , Cheetham S , Maleuwe P , Ghatei M , Bloom S , Dhillo W

Background: The novel peptide prokineticin-2 (PK2) has recently been implicated in the regulation of a number of physiological processes; including regulating gastrointestinal motility, spermatogenesis, neurogenesis and circadian rhythms. PK2 is a cysteine rich protein which mediates its effects via the prokineticin receptors which are expressed in several hypothalamic nuclei known to regulate food intake. We therefore hypothesised that PK2 may be an important endogenous regul...